DRAXIN as a Novel Diagnostic Marker to Predict the Poor Prognosis of Glioma Patients
Open Access
- 30 August 2022
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 72 (10) , 2136-2149
Abstract
An increasing number of evidences have shown that the carcinogenic effect of DRAXIN plays an important role in the malignant process of tumors, but the mechanism of its involvement in glioma has not yet been revealed. The main aim of this study is to explore the relationship between DRAXIN and the prognosis and pathogenesis of glioma through a large quality of data analysis. Firstly, thousands of tissue samples with clinical information were collected based on various public databases. Then, a series of bioinformatics analyses were performed to mine data from information of glioma samples extracted from several reputable databases to reveal the key role of DRAXIN in glioma development and progression, with the confirmation of basic experiments. Our results showed that high expression of the oncogene DRAXIN in tumor tissue and cells could be used as an independent risk factor for poor prognosis in glioma patients and was strongly associated with clinical risk features. The reverse transcription-quantitative PCR technique was then utilized to validate the DRAXIN expression results we obtained. In addition, co-expression analysis identified, respectively, top 10 genes that were closely associated with DRAXIN positively or negatively. Finally, in vitro experiments demonstrated that knockdown of DRAXIN significantly inhibited proliferation and invasion of glioma cell. To sum up, this is the first report of DRAXIN being highly expressed in gliomas and leading to poor prognosis of glioma patients. DRAXIN may not only benefit to explore the pathogenesis of gliomas, but also serve as a novel biological target for the treatment of glioma.Keywords
All Related Versions
Funding Information
- The Thousand Talents Plan of Central Plains (ZYQR20191212)
This publication has 32 references indexed in Scilit:
- NCBI GEO: archive for functional genomics data sets—updateNucleic Acids Research, 2012
- Therapeutic targeting of VEGF in the treatment of glioblastomaExpert Opinion on Therapeutic Targets, 2012
- Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomasClinical Neurology and Neurosurgery, 2012
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Molecular diagnostics of gliomas: state of the artActa Neuropathologica, 2010
- Draxin, a repulsive axon guidance protein, is involved in hippocampal developmentNeuroscience Research, 2010
- Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profileMolecular Cancer, 2008
- Identification of coherent patterns in gene expression data using an efficient biclustering algorithm and parallel coordinate visualizationBMC Bioinformatics, 2008
- GSEA-P: a desktop application for Gene Set Enrichment AnalysisBioinformatics, 2007